Omega Diagnostics Share Discussion Threads

[rivaldo] 21/4/2016 09:45

Finncap retain their 28p valuation on ODX today:

[longshanks] 21/4/2016 08:00

The CD4 update is pretty much as I anticipated - which is gratifying.They are looking to eliminate the ATE all together but in the meantime have contained it to 32 Deg C.They clearly need it to be able to operate at "near blood temperature" because of where the test will be applied. The question is how close they are to getting a consistent result at 35 DegC.Good positive update overall and I am happy to hold.

[hyperboreus] 21/4/2016 07:54

Still work to do but this comprehensive update is just what was required at this stage in my opinion.

During the last 12 months I have almost quadrupled my original holding adding anywhere between 13p - 14.50p

The risk/reward ratio always appeared to be very attractive at these levels given the CD4 & allergy tests businesses and the appointment of Colin King last year and the subsequent announcement of his options package further reinforced my view.

Plenty to look forward here imho

[barrywhit] 21/4/2016 07:29

Worth waiting for. good update....Happy to continue to hold and add...

[rivaldo] 21/4/2016 07:17

Nice timing Hyperboreus - a good trading update out today:

- PBT in line with expectations at £1.2m-£1.3m
- revenues up 5%, with Food Intolerance still growing fast, more than compensating for the German allergy business
- new Allersys® allergy tests ready for launch
- CD4 progressing slowly, but steadily and just a matter of engineering now having found the cause of the problem

At around 1.3p historic EPS, and two blue sky opportunities in for free, ODX remains much too cheap imho.

[hyperboreus] 20/4/2016 16:10

I'm partly responsible for today's move guys so bearing in mind I first jumped aboard over 4 years ago I wouldn't read that much into it!

[rivaldo] 20/4/2016 15:23

Yes, although it's only just later as it's usually anywhere from the 10th-15th April.

Given today's move it'll be interesting to see if the trading statement arrives tomorrow morning :o))

[barrywhit] 20/4/2016 07:59

Don't think we have ever been this late with the trading statement. Should make good/interesting reading when it does arrive, updates on many fronts....

[longshanks] 19/4/2016 08:10

They know the cause of the stability issue and have been systematically testing out the solution they had arrived at. Because the issue took time to manifest, this redevelopment phase may well not yet have completed.Once satisfied that they have a stable product they will move once again to field testing and validation.We should get an updated schedule on this, but they did painfully point this out last year that the process will be necessarily slow so as to avoid any re-work again.

[p1nkfish] 16/4/2016 22:45

most probably would warrant an rns.

no way to know when the problem will be solved norto know if it is to be announced with the results or might possibly be responsible for any delay in results so they can announce on the day.

[spacecake] 16/4/2016 17:05

If ODX had solved the stability issue with the CD4 test and moved to production would this ave required an RNS ?

[p1nkfish] 14/4/2016 21:00

If not too positive this time, will be next.

[barrywhit] 14/4/2016 15:18

Here is hoping for a positive RNS Tomorrow or Monday......gla

[rivaldo] 14/4/2016 09:22

I find the market is often surprised, especially as regards smaller companies, where share prices are often overly affected by just one institutional seller (or buyer). PEG's two great RNS's this morning are just one example.

Nice snippet here:



"On the other hand, Omega Diagnostics, a Scottish company that has been operating in India since 1992, inaugurated their first greenfield manufacturing facility at the International Biotech Park, Pune in November last year. With an investment of $0.9 million, the company estimates that it could be employing up to 50 people, including high quality positions in production management and technical/ quality control roles over the next 12 months.

With the Indian healthcare market growing rapidly over the recent years, the move to establish a manufacturing base in India is a logical and exciting step forward for the Omega Diagnostics Group. The company sees potential for major growth, not just in the Indian domestic market, but also to export products produced in Pune to their global distribution network which covers over 100 countries."

[p1nkfish] 12/4/2016 11:30

Problem is the market is rarely surprised when it expects news so news may be in the price already and the price is telling us the news?

Hope I'm wrong,

[rivaldo] 11/4/2016 15:24

As previously stated, the year end trading update has been 14th and 15th April the last two years, so any day now.

Hopefully a positive CD4 update to come, along with reasonable - or better, given improved currency movements - core trading numbers.

[arthur_lame_stocks] 11/4/2016 13:16

Maybe the current weakness in the share price is due to a lack of newsflow regarding CD4 development?

[longshanks] 11/4/2016 12:50

Yes. Good bread and butter businesses ticking along with potential game changing initiatives in the pipeline.I am not totally sold on the iSYS array opportunities but CD4 will introduce a revolutionary way of treating HIV in the developing world - and could be a springboard for many other similar initiatives.

[arthur_lame_stocks] 11/4/2016 11:04

Thanks for that rivaldo.

[rivaldo] 11/4/2016 07:20

ODX's investor Hygea VCT today summarise progress at ODX in their Annual Report as follows:



"Omega Diagnostics plc

Background: Omega Diagnostics plc ("Omega") listed on AIM via a reverse acquisition in 2006. It is a healthcare diagnostics business providing IVD products for use in hospitals, blood banks, clinics and laboratories in over 100 countries and it specialises in the areas of Food Intolerance, Allergy and Autoimmune Disease, and Infectious Disease.

One of its products is Food Detective for home testing of allergies brought about by 59 commonly eaten foods. In December 2010 Allergopharma was acquired by Omega for £7.75 million - it produces manual assays for testing for allergies - part of the strategy for developing the Allergopharma business is to leverage off Omega's distribution reach, and take the assays into the much larger automated market using Omega's Genarrayt platform and the IDS-iSYS platform, which has been licensed from AIM listed Immunodiagnostic Systems Holdings.

In June 2012, Omega entered into agreements providing it with worldwide exclusive access to two point-of-care tests, one for CD4 and the other for Syphilis. Testing for CD4 T- cells is a vital component for the management and care of people suffering from HIV, which affects c.33 million people worldwide - the key competition is currently flow cytometry, which involves laboratories and centralised testing.

In summary, the group currently has two key projects, each of which has transformational growth potential to augment the growth potential of the existing established businesses.

Update since 2014: both of the transformational projects are progressing and the IDS-iSYS project is expected to achieve CE marking by mid 2016. The interim results to September 2015 showed sales of £6.15 million (2014: £5.7 million) and adjusted pre-tax profit of £351,000 (2014: £410,000), after increasing overheads by £279,000 in order to implement growth plans."

[rivaldo] 08/4/2016 12:20

Nice mention for ODX in this week's Shares magazine about companies which are fighting the "growing allergy epidemic":

"Testing kit maker Omega Diagnostics (ODX:AIM) makes allergy tests for more than
600 allergens, alongside its HIV and tuberculosis business. It has more than 20 years’ experience in the development of products for the diagnosis of allergic disease."

[p1nkfish] 08/4/2016 06:40

Wedge pattern. Decision time for break up or down approaching. See no reason to be negative.

[longshanks] 07/4/2016 12:03

We need positive news on the CD4 device to really take off but I am happy with the relatively steady progress achieved across the operations over the last few years.Not long IMO before they are generating strong cash flows; strong enough to support a progressive dividend.

[rivaldo] 07/4/2016 11:57

Looks like a series of higher lows over the last few months to me.

Nice 100,000 buy at 14.47p today.

[buywell3] 06/4/2016 15:19

Not much of an uptrend in my view

More like a wedge